Dr. Neil is Chief Executive Officer of Avalo Therapeutics (formerly Cerecor, Inc.), a public biotechnology company since February 2022. He previously served as Avalo’s Chief Scientific Officer following its merger with Aevi Genomic Medicine, where he had been CSO from 2013 to 2020. Previously, Dr. Neil was a Partner at Apple Tree Partners and held senior roles at major pharmaceutical companies, including Corporate VP of Science & Technology and Group President at Johnson & Johnson, VP of R&D at Merck KGaA/EMD Pharmaceuticals, and VP of Clinical Research at AstraZeneca and Astra Merck. He currently serves on the board of Celldex Therapeutics and has served on the boards of Arena Pharmaceuticals, GTx, Inc., and Zura Bio. Dr. Neil is a board member of the Center for Discovery and Innovation and the founding Chairman of TransCelerate Biopharma. His previous board service includes the Reagan Udall Foundation for the FDA, the Foundation for the NIH, and the NIH Science Management Review Board. He also chaired the PhRMA Science and Regulatory Executive Committee and PhRMA Foundation Board. Dr. Neil holds a B.S. and M.D. from the University of Saskatchewan, with postdoctoral training at the University of Toronto and the Scripps Research Institute.